Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $25.0 million.

  • Spyre Therapeutics' Cash from Investing Activities fell 4151.15% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.6 million, marking a year-over-year increase of 6944.72%. This contributed to the annual value of -$353.3 million for FY2024, which is 22592.97% down from last year.
  • As of Q3 2025, Spyre Therapeutics' Cash from Investing Activities stood at $25.0 million, which was down 4151.15% from $79.0 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Cash from Investing Activities registered a high of $79.0 million during Q2 2025, and its lowest value of -$170.5 million during Q4 2024.
  • Its 5-year average for Cash from Investing Activities is -$17.0 million, with a median of $6.8 million in 2023.
  • In the last 5 years, Spyre Therapeutics' Cash from Investing Activities surged by 80133.33% in 2023 and then crashed by 188281.07% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Cash from Investing Activities (Quarter) stood at $9.7 million in 2021, then surged by 44.88% to $14.0 million in 2022, then plummeted by 351.94% to -$35.3 million in 2023, then crashed by 383.51% to -$170.5 million in 2024, then soared by 114.66% to $25.0 million in 2025.
  • Its last three reported values are $25.0 million in Q3 2025, $79.0 million for Q2 2025, and -$61000.0 during Q1 2025.